Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Phase 4 Study to Evaluate the Efficacy and Safety of Entyvio (Vedolizumab IV) in the Treatment of Chronic Pouchitis (EARNEST)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jun 2023
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary) ; Ciprofloxacin
- Indications Pouchitis
- Focus Therapeutic Use
- Acronyms EARNEST
- Sponsors Takeda
- 09 May 2023 Results presented at the Digestive Disease Week 2023
- 30 Mar 2023 According to a Takeda media release, Canadian investigators played an important role in the development and execution of this study.
- 30 Mar 2023 According to a Takeda media release, results from this trial were published in New England Journal of Medicine.